Indegene

Why is Indegene Ltd falling/rising?

As of 23-Jun, Indegene Ltd's stock price has fallen to 530.00, down 2.06% after a trend reversal. Despite this decline, the stock has shown positive performance over the past week and month, and investor participation has increased significantly.

As of 23-Jun, Indegene Ltd's stock price is falling, currently at 530.00, which reflects a decrease of 11.15 or 2.06%. This decline follows a trend reversal after seven consecutive days of gains. The stock touched an intraday low of Rs 527.5, indicating a drop of 2.52% during the day. <BR><BR>Despite the recent downturn, the stock has shown positive performance over the past week and month, with increases of 2.74% and 4.32%, respectively. However, the overall sentiment in the IT - Software sector has been negative, with the sector experiencing a decline of 2.18%. <BR><BR>Investor participation has risen, as evidenced by a significant increase in delivery volume, which was up by 60.09% compared to the five-day average. Additionally, Indegene Ltd is trading above its moving averages for various periods, suggesting some underlying strength. <BR><BR>On a broader scale, while the stock has generated a return of -7.34% over the past year, its profits have increased by 2.4%, and the company is net-debt free, which may contribute to its fair valuation. However, the current market conditions and sector performance appear to be influencing the stock's recent decline.

Which are the latest news on Indegene?

Should I buy, sell or hold Indegene Ltd?

What does Indegene do?

Indegene Ltd is a small-cap healthcare services company that reported net sales of 1,003 Cr and a net profit of 80 Cr for March 2026. It has a market cap of INR 12,647 Cr and key metrics include a P/E ratio of 30.00 and a dividend yield of 0.38%.

Overview:<BR>Indegene Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History:<BR>Indegene Limited was incorporated in 1998 as Indegene Lifesystems Private Limited. The company underwent a name change to Indegene Private Limited in 2016 and later converted to a public company, adopting the name Indegene Limited in November 2022. The most recent quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,003 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 80 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 12,647 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 30.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.38% <BR>Debt-Equity: -0.43 <BR>Return on Equity: 13.27% <BR>Price to Book: 4.04 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Indegene?

As of 10th June, Indegene Ltd has a market capitalization of 12,647.00 Cr, with recent net sales of 3,510.50 Cr and a net profit of 401.10 Cr.

As of 10th June, Indegene Ltd has a market capitalization of 12,647.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Indegene reported Net Sales of 3,510.50 Cr and a Net Profit of 401.10 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,615.60 Cr and Total Assets of 3,236.10 Cr.

Who are the peers of the Indegene?

Indegene's peers include Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Health, Thyrocare Tech., Suven Life Sciences, Vimta Labs, and Krsnaa Diagnost. Management risk varies from excellent to below average among peers, with Thyrocare Tech. showing the highest 1-year return at 61.08% and Syngene Intl. the lowest at -31.36%, while Indegene's return is -15.60%.

Peers: The peers of Indegene are Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, Metropolis Healt, Thyrocare Tech., while Good management risk is found at Syngene Intl., Poly Medicure, Vijaya Diagnost., and the rest. Average management risk is noted for Indegene, Vimta Labs, and Krsnaa Diagnost., while Below Average management risk is present at Suven Life Scie. Growth is consistently below average across all peers, with Indegene, Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest showing this trend. Capital Structure is excellent for Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Vimta Labs, and Krsnaa Diagnost., while Suven Life Scie. has a below-average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Thyrocare Tech. at 61.08%, while the lowest is Syngene Intl. at -31.36%. Indegene's own 1-year return is -15.60%, which is higher than Syngene Intl.'s but lower than Thyrocare Tech.'s. Additionally, Suven Life Scie. and Krsnaa Diagnost. have negative six-month returns.

Are Indegene Ltd latest results good or bad?

Indegene Ltd's latest results show strong revenue growth of 32.80% year-on-year, reaching ₹1,003.40 crores, but profitability has declined significantly, with net profit down 32.23% to ₹79.70 crores and margins contracting, raising concerns about operational health. Investors should monitor how the company addresses these challenges moving forward.

Indegene Ltd's latest results present a mixed picture, showcasing strong revenue growth but significant challenges in profitability. For the quarter ending March 2026, the company reported a remarkable revenue increase of 32.80% year-on-year, reaching ₹1,003.40 crores, which is a record high for the company. However, this impressive top-line performance was overshadowed by a sharp decline in net profit, which fell by 32.23% year-on-year to ₹79.70 crores. <BR><BR>The profitability metrics are concerning, with the PAT margin contracting to 7.94% from 15.56% in the same quarter last year, marking the lowest quarterly margin in recent periods. Additionally, the operating margin also declined, indicating fundamental issues in cost management and operational efficiency. <BR><BR>Overall, while the revenue growth is a positive sign, the significant drop in profitability and margin compression raises serious concerns about the company's operational health and sustainability. Investors may need to closely monitor how the company addresses these challenges in the coming quarters.

When is the next results date for Indegene Ltd?

Indegene Ltd will announce its results on 29 April 2026.

Indegene Ltd is scheduled to declare its results on 29 April 2026.

Is Indegene technically bullish or bearish?

As of December 1, 2025, the technical trend is mildly bearish due to bearish momentum from the MACD and KST, daily moving averages, and Bollinger Bands, despite conflicting signals from Dow Theory and a lack of momentum indicated by the RSI.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the weekly MACD and KST both indicating bearish momentum, along with daily moving averages also showing a bearish trend. The Bollinger Bands on the weekly chart confirm a bearish outlook, while the Dow Theory indicates a mildly bullish stance on the weekly timeframe, suggesting some conflicting signals. The RSI shows no signal on both weekly and monthly timeframes, indicating a lack of momentum. Overall, the indicators suggest a cautious approach as the stock remains below its previous close and has a significant decline over the past year.

How has been the historical performance of Indegene?

Indegene has demonstrated consistent financial growth over the past four years, with net sales increasing from 1,664.61 Cr in March 2022 to 2,839.30 Cr in March 2025, alongside significant rises in operating profit and net profit. The company has also reduced its total debt to zero by March 2025, indicating strong overall performance.

Answer:<BR>Indegene has shown a consistent growth trajectory in its financial performance over the past four years, with significant increases in net sales, operating profit, and net profit.<BR><BR>Breakdown:<BR>Indegene's net sales have risen from 1,664.61 Cr in March 2022 to 2,839.30 Cr in March 2025, reflecting a robust growth trend. Total operating income has mirrored this increase, reaching 2,839.30 Cr in March 2025, up from 1,664.61 Cr in March 2022. The company's operating profit (PBDIT) also demonstrated substantial growth, climbing from 312.81 Cr in March 2022 to 641.50 Cr in March 2025. Profit before tax followed suit, increasing from 226.50 Cr in March 2022 to 539.30 Cr in March 2025, while profit after tax rose from 162.82 Cr to 406.70 Cr in the same period. The company's total assets have expanded significantly, from 1,284.31 Cr in March 2022 to 3,236.10 Cr in March 2025, alongside a reduction in total debt, which dropped to 0.00 Cr in March 2025 from 403.10 Cr in March 2024. Cash flow from operating activities has also been positive, amounting to 441.00 Cr in March 2025, although cash flow from investing activities was negative at -677.00 Cr. Overall, Indegene's financial metrics indicate a strong and improving performance over the years.

Who are the top shareholders of the Indegene?

The top shareholders of Indegene include Nadathur Fareast Pte Ltd with 21.96%, 18 mutual fund schemes holding 2.65%, and 72 foreign institutional investors owning 5.24%. Individual investors hold 11.34%, with no pledged promoter holdings or a single dominant promoter.

The top shareholders of Indegene include Nadathur Fareast Pte Ltd, which holds the largest public share at 21.96%. Additionally, the company has a diverse shareholder base with 18 mutual fund schemes collectively holding 2.65% and 72 foreign institutional investors (FIIs) holding 5.24%. Individual investors also have a significant presence, owning 11.34% of the shares. Notably, there are no pledged promoter holdings, and there isn't a single promoter with the highest holding.

Is Indegene overvalued or undervalued?

As of June 17, 2025, Indegene is considered undervalued with an attractive valuation grade, reflected by a PE ratio of 34.27, an EV to EBITDA of 23.16, and a strong ROCE of 43.13%, despite its higher ratios compared to peers like TCS and Infosys and a year-to-date return of -3.89% versus the Sensex's 4.41%.

As of 17 June 2025, the valuation grade for Indegene has moved from fair to attractive, indicating a more favorable outlook for the company. The current analysis suggests that Indegene is undervalued. Key ratios include a PE ratio of 34.27, an EV to EBITDA of 23.16, and a ROCE of 43.13%, which reflects strong operational efficiency.<BR><BR>In comparison to peers, Indegene's PE ratio is notably higher than TCS at 26.2 and Infosys at 25.51, while its EV to EBITDA is also above TCS's 18.32. This suggests that while Indegene is trading at a premium compared to some peers, its robust ROCE and PEG ratio of 0.00 indicate significant growth potential. Despite recent stock performance trailing the Sensex, with a YTD return of -3.89% compared to the Sensex's 4.41%, the overall valuation metrics support the conclusion that Indegene is currently undervalued.

Has Indegene declared dividend?

Indegene Ltd has declared a 100% dividend with an ex-date of June 13, 2025. However, the dividend yield is 0%, and total returns over longer periods show no growth, indicating mixed performance.

Indegene Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Ex-date: 13 Jun 25<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Indegene experienced a price return of -6.36%, a dividend return of 0.34%, resulting in a total return of -6.02%.<BR><BR>Over the past year, the company achieved a price return of 9.98%, a dividend return of 0.36%, leading to a total return of 10.34%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, Indegene reported no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Similarly, over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the company again had no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Indegene has declared a dividend, the dividend yield remains at 0%, and the total returns over longer periods show no growth, indicating a mixed performance in terms of returns.